Dyne Therapeutics (DYN) Stock Analysis

What Dyne Therapeutics does

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

Key metrics

ETFs linked to DYN

Broad-market and Healthcare sector ETFs an investor holding Dyne Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how DYN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Dyne Therapeutics?

Dyne Therapeutics trades under the ticker DYN on NASDAQ.

Which exchange is DYN listed on?

DYN is listed on NASDAQ.

What sector does Dyne Therapeutics operate in?

Dyne Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze DYN in a portfolio?

PortView shows DYN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.